文献速递外周动脉疾病

膝下旁路术与膝下腔内治疗在孤立性膝下闭塞性疾病中的比较

Popliteal-distal bypass versus infra-popliteal endovascular therapy for infra-popliteal occlusive disease.
PubMed 文献 · J Vasc Surg · 2025-08-05

本研究基于Vascular Quality Initiative数据,比较膝下旁路术(PDB)与单纯膝下腔内治疗(ET)在慢性肢体威胁性缺血(CLTI)患者中的真实世界结局。经倾向性评分匹配后,PDB虽围术期死亡和并发症更高、住院更长,但1年生存、无截肢生存、一期通畅率更优且主要不良肢体事件更低。

要点

  • PDB围术期死亡和并发症高于ET,但1年无截肢生存和通畅率更优。
  • PDB使用率从2010年25%降至2023年5%,ET相应从75%升至95%。
  • 膝上与膝下来源、胫动脉与足部动脉流出道的PDB无截肢生存无差异。

核心结论

  • 尽管PDB使用率下降,其长期无截肢生存、通畅率和保肢仍优于膝下ET,但围术期死亡和并发症更高。

研究设计与样本

  • 回顾性队列研究,基于Vascular Quality Initiative 2010至2024年数据。
  • PDB定义为单段大隐静脉、起自膝上或膝下腘动脉的旁路,排除更近端同期干预或旁路。
  • 膝下ET定义为胫动脉球囊扩张、斑块旋切和/或支架,排除同期旁路或股腘干预。
  • 采用3:1最近邻倾向性评分匹配无放回,匹配3619例PDB与10857例ET。

主要发现

  • PDB住院6天 vs ET 1天(P < .001)。
  • PDB院内死亡率1.4% vs ET 0.9%(P = .021)。
  • PDB心肌梗死2.5% vs ET 0.4%(P < .001),急性肾损伤7.2% vs 1.4%(P < .001)。
  • PDB肺炎2.2% vs ET 0.7%(P < .001),手术部位感染2.9% vs 0.0%(P < .001)。
  • 1年随访PDB生存86.7% vs ET 83.9%(P < .001),无截肢生存72.6% vs 65.9%(P < .001),一期通畅率73.6% vs 69.0%(P = .002),主要不良肢体事件25.9% vs 30.1%(P = .007)。

关键数值与推荐

  • PDB使用率从2010年25%降至2023年5%,ET从75%升至95%。
  • 膝上PDB无截肢生存73.6% vs ET 65.9%(P < .001),膝下PDB 71.9% vs ET 65.9%(P < .001),膝上与膝下PDB间无差异(P = .407)。
  • 胫动脉PDB无截肢生存72.3% vs ET 65.9%(P < .001),足部动脉PDB 72.6% vs ET 65.9%(P < .001),两者间无差异(P = .860)。

临床怎么用

  • 对孤立性膝下闭塞性病变CLTI患者,需术前仔细评估风险,权衡PDB围术期风险与长期获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Isolated infrapopliteal occlusive disease poses significant clinical challenges due to limited durable treatment options and poor limb salvage and survival rates. Although endovascular therapy (ET) has gained prominence for its minimally invasive approach, popliteal-distal bypass (PDB) provides an effective open approach that minimizes dissection and length of bypass required. This study aims to compare real-world outcomes of PDB vs infrapopliteal ET for chronic limb-threatening ischemia (CLTI) secondary to isolated infrapopliteal occlusive disease. METHODS: Patients who underwent a PDB or isolated infrapopliteal ET for CLTI between 2010 and 2024 were identified in the Vascular Quality Initiative. PDB was defined as a bypass using single-segment great saphenous vein originating from an above-knee or below-knee popliteal artery inflow; patients with a concomitant more proximal peripheral vascular intervention or bypass were excluded. Infrapopliteal ET was defined as transluminal balloon angioplasty, atherectomy, and/or stenting of a tibial artery; patients with a concomitant bypass or femoropopliteal intervention were excluded. Three-to-one nearest-neighbor propensity score matching without replacement was performed to ensure balance of covariates between the two comparison groups. Kaplan-Meier and Cox regression analysis were used to estimate long-term event rates and evaluate the association of type of intervention with the long-term outcomes of survival, amputation-free survival, primary patency, and major adverse limb events defined as the composite outcome of amputation and/or reintervention. RESULTS: A total of 3619 patients who underwent PDB were matched to 10,857 patients who underwent isolated infrapopliteal ET. All baseline characteristics and demographics were balanced after propensity score matching. The utilization of PDB for isolated infrapopliteal occlusive disease decreased from 25% to 5% between 2010 and 2023, whereas that of infrapopliteal ET increased from 75% to 95%. PDB was associated with a significantly longer hospital stay (6 days vs 1 day; P < .001) and higher rates of in-hospital mortality (1.4% vs 0.9%; P = .021), myocardial infarction (2.5% vs 0.4%; P < .001), acute kidney injury (7.2% vs 1.4%; P < .001), pneumonia (2.2% vs 0.7%; P < .001), and surgical site infection (2.9% vs 0.0%; P < .001) compared with infrapopliteal ET. At 1-year follow-up, PDB was associated with significantly higher survival (86.7% vs 83.9%; P < .001), amputation-free survival (72.6% vs 65.9%; P < .001), and primary patency (73.6% vs 69.0%; P = .002) and lower major adverse limb events (25.9% vs 30.1%; P = .007) compared with infrapopliteal ET. PDB was associated with significantly higher amputation-free survival compared with infrapopliteal ET for both above-knee PDB (73.6% vs 65.9%; P < .001) and below-knee PDB (71.9% vs 65.9%; P < .001), with no difference observed between above-knee and below-knee PDB (P = .407). Similarly, PDB was associated with significantly higher amputation-free survival compared with infrapopliteal ET for both PDB to a tibial artery (72.3% vs 65.9%; P < .001) and PDB to a pedal artery (72.6% vs 65.9%; P < .001), with no difference observed between PDB to a tibial artery and PDB to a pedal artery (P = .860). CONCLUSIONS: Although its use has declined over the past decade, PDB continues to provide superior long-term outcomes in amputation-free survival, patency, and limb salvage compared with infrapopliteal ET in patients with infrapopliteal occlusive disease, albeit with a higher rate of perioperative mortality and morbidity. Careful preoperative risk assessment and thoughtful patient selection are essential to optimize the outcomes of isolated infrapopliteal interventions, ensuring that immediate procedural risks are appropriately weighed against the potential for improved longer-term outcomes in this patient population.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Chamseddine H, Halabi M, Shepard A, et al. Popliteal-distal bypass versus infra-popliteal endovascular therapy for infra-popliteal occlusive disease. J Vasc Surg. 2025. PMID: 40769463. doi:10.1016/j.jvs.2025.07.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。